profit from every $100 of sales.
$0$100
Mereo BioPharma Group
$0.30+0.95% today
+34.6% in 1 year
1-year low $0.221-year high $0.72
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Mereo BioPharma Group sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $500,000 in 2025, with -$41.9 million of profit last year.
SalesProfit
Mereo BioPharma Group vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Mereo BioPharma Group | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Mereo BioPharma Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 10 | 0 | 1 | |
| 1 | 7 | 0 | 0 | |
| -53 | -27 | -46 | -38 | |
| -38 | -26 | -41 | -40 | |
| -42 | -29 | -43 | -42 | |
| -0.36 | -0.20 | -0.30 | -0.25 | |
| – | 74.3% | – | 73.4% | |
| – | -271.4% | – | -7,651.4% | |
| – | -294.7% | – | -8,375.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 77 | 66 | 76 | 46 |
| Cash | 68 | 57 | 70 | 41 |
| Total debt | 15 | 6 | 6 | 0 |
| Total liabilities | 26 | 16 | 15 | 5 |
| 51 | 51 | 61 | 41 | |
| 114 | 132 | 148 | 159 | |
| -45.9% | -37.9% | -49.1% | -80.0% | |
| -82.1% | -58.3% | -70.9% | -102.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -49 | -21 | -33 | -31 | |
| 0 | 0 | 1 | 0 | |
| -49 | -22 | -34 | -31 | |
| Dividends paid | 0 | – | – | – |
| – | – | – | – | |
| 5 | 5 | 7 | 8 |
Valuation
- –
- –
- –
- 1.0×
- 95.1×
- –
- –
- -65.8%
- -88.0%
- 0.0%
Profitability
- 73.4%
- -7,651.4%
- -8,375.6%
- -8,656.4%
- -96.9%
- -53.8%
- -83.0%
- -91.2%
- -97.3%
- 3,464.0%
Growth
- −77.6%
- –
- +7.6%
- –
- +8.1%
Financial health
- -1.0×
- 0.00
- 0.4%
- -159.0×
- 10.46
- 10.46
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 953
Bottom 1%of 871
Bottom 1%of 988
What analysts expect
- Average price target
- $0.83
- Range
- $0.50 – $1.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.01 | 0.02 | −150.0% |
| Mar 19, 2026 | -0.01 | -0.01 | +0.0% |
| Nov 10, 2025 | -0.01 | -0.01 | −20.0% |
| Aug 12, 2025 | -0.02 | -0.01 | −100.0% |
| May 13, 2025 | -0.02 | -0.01 | −100.0% |
| Mar 26, 2025 | -0.01 | -0.02 | +50.0% |
| Nov 12, 2024 | -7.69 | -1.36 | −465.4% |
| Aug 13, 2024 | -0.02 | -0.78 | +97.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
67Pass
Philip Fisher
52No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
51No pass
Terry Smith
45No pass
Questions about Mereo BioPharma Group
Is Mereo BioPharma Group a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Mereo BioPharma Group AI analysis
What does Mereo BioPharma Group do?
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. It is in Biotechnology.
Does Mereo BioPharma Group pay a dividend?
No. Mereo BioPharma Group does not pay a dividend at the moment.
Is Mereo BioPharma Group stock halal?
No. Mereo BioPharma Group does not pass our halal screen: its cash and confirmed interest-bearing investments are 86% of its market value, at or above the 33% limit. How we check
How has Mereo BioPharma Group stock done over the past year?
Up 34.6% over the past twelve months, to $0.30. It traded between $0.22 and $0.72 and is 58.5% below its high.
Who are Mereo BioPharma Group's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Mereo BioPharma Group's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.